206 related articles for article (PubMed ID: 2339131)
1. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice.
Zhou JY; Norman AW; Chen DL; Sun GW; Uskokovic M; Koeffler HP
Proc Natl Acad Sci U S A; 1990 May; 87(10):3929-32. PubMed ID: 2339131
[TBL] [Abstract][Full Text] [Related]
2. Structure-function studies on analogues of 1 alpha,25-dihydroxyvitamin D3: differential effects on leukemic cell growth, differentiation, and intestinal calcium absorption.
Norman AW; Zhou JY; Henry HL; Uskokovic MR; Koeffler HP
Cancer Res; 1990 Nov; 50(21):6857-64. PubMed ID: 2208153
[TBL] [Abstract][Full Text] [Related]
3. Growth inhibitory effects on human colon adenocarcinoma-derived Caco-2 cells and calcemic potential of 1 alpha,25-dihydroxyvitamin D3 analogs: structure-function relationships.
Bischof MG; Redlich K; Schiller C; Chirayath MV; Uskokovic M; Peterlik M; Cross HS
J Pharmacol Exp Ther; 1995 Dec; 275(3):1254-60. PubMed ID: 8531089
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of cyclooxygenase-2 (COX-2) by 1alpha,25-dihydroxy-16-ene-23-yne-vitamin D3, a less calcemic vitamin D analog.
Aparna R; Subhashini J; Roy KR; Reddy GS; Robinson M; Uskokovic MR; Venkateswara Reddy G; Reddanna P
J Cell Biochem; 2008 Aug; 104(5):1832-42. PubMed ID: 18348265
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of the cell differentiating agent 1alpha,25(OH)2-16-ene-23-yne vitamin D3 by leukemic cells.
Satchell DP; Norman AW
J Steroid Biochem Mol Biol; 1996 Jan; 57(1-2):117-24. PubMed ID: 8645610
[TBL] [Abstract][Full Text] [Related]
6. 1alpha,25-dihydroxy-24-oxo-16-ene vitamin D3, a metabolite of a synthetic vitamin D3 analog, 1alpha,25-dihydroxy-16-ene vitamin D3, is equipotent to its parent in modulating growth and differentiation of human leukemic cells.
Siu-Caldera ML; Clark JW; Santos-Moore A; Peleg S; Liu YY; Uskoković MR; Sharma S; Reddy GS
J Steroid Biochem Mol Biol; 1996 Dec; 59(5-6):405-12. PubMed ID: 9010346
[TBL] [Abstract][Full Text] [Related]
7. 1alpha,25-dihydroxy-16-ene-23-yne-vitamin D3 and 1alpha,25-dihydroxy-16-ene-23-yne-20-epi-vitamin D3: analogs of 1alpha,25-dihydroxyvitamin D3 that resist metabolism through the C-24 oxidation pathway are metabolized through the C-3 epimerization pathway.
Reddy GS; Rao DS; Siu-Caldera ML; Astecker N; Weiskopf A; Vouros P; Sasso GJ; Manchand PS; Uskokovic MR
Arch Biochem Biophys; 2000 Nov; 383(2):197-205. PubMed ID: 11185554
[TBL] [Abstract][Full Text] [Related]
8. 1,25(OH)2-16ene-vitamin D3 is a potent antileukemic agent with low potential to cause hypercalcemia.
Jung SJ; Lee YY; Pakkala S; de Vos S; Elstner E; Norman AW; Green J; Uskokovic M; Koeffler HP
Leuk Res; 1994 Jun; 18(6):453-63. PubMed ID: 8207963
[TBL] [Abstract][Full Text] [Related]
9. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
Kubota T; Koshizuka K; Koike M; Uskokovic M; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3370-5. PubMed ID: 9699668
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D3 analogs: effect on leukemic clonal growth and differentiation, and on serum calcium levels.
Pakkala S; de Vos S; Elstner E; Rude RK; Uskokovic M; Binderup L; Koeffler HP
Leuk Res; 1995 Jan; 19(1):65-72. PubMed ID: 7837819
[TBL] [Abstract][Full Text] [Related]
11. Antileukemic effect of a synthetic vitamin D3 analog, HY-11, with low potential to cause hypercalcemia.
Yoon JS; Kim JY; Park HK; Kim ES; Ahn KS; Yoon SS; Cho CG; Kim BK; Lee YY
Int J Oncol; 2008 Feb; 32(2):387-96. PubMed ID: 18202761
[TBL] [Abstract][Full Text] [Related]
12. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo.
Schwartz GG; Hill CC; Oeler TA; Becich MJ; Bahnson RR
Urology; 1995 Sep; 46(3):365-9. PubMed ID: 7660511
[TBL] [Abstract][Full Text] [Related]
13. Antineoplastic effect and toxicity of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 in athymic mice with Y-79 human retinoblastoma tumors.
Sabet SJ; Darjatmoko SR; Lindstrom MJ; Albert DM
Arch Ophthalmol; 1999 Mar; 117(3):365-70. PubMed ID: 10088815
[TBL] [Abstract][Full Text] [Related]
14. Potent antiproliferative effects of 25-hydroxy-16-ene-23-yne-vitamin D₃ that resists the catalytic activity of both CYP27B1 and CYP24A1.
Rhieu SY; Annalora AJ; LaPorta E; Welsh J; Itoh T; Yamamoto K; Sakaki T; Chen TC; Uskokovic MR; Reddy GS
J Cell Biochem; 2014 Aug; 115(8):1392-402. PubMed ID: 24535953
[TBL] [Abstract][Full Text] [Related]
15. 5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells.
Hisatake J; Kubota T; Hisatake Y; Uskokovic M; Tomoyasu S; Koeffler HP
Cancer Res; 1999 Aug; 59(16):4023-9. PubMed ID: 10463602
[TBL] [Abstract][Full Text] [Related]
16. In vivo and in vitro effect of 1,25-dihydroxyvitamin D3 and 1,25-dihydroxy-16-ene-23-yne-vitamin D3 on the proliferation and differentiation of avian chondrocytes: their role in tibial dyschondroplasia.
Farquharson C; Rennie JS; Loveridge N; Whitehead CC
J Endocrinol; 1996 Mar; 148(3):465-74. PubMed ID: 8778225
[TBL] [Abstract][Full Text] [Related]
17. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
18. Growth inhibition of HT-29 human colon cancer cells by analogues of 1,25-dihydroxyvitamin D3.
Shabahang M; Buras RR; Davoodi F; Schumaker LM; Nauta RJ; Uskokovic MR; Brenner RV; Evans SR
Cancer Res; 1994 Aug; 54(15):4057-64. PubMed ID: 8033137
[TBL] [Abstract][Full Text] [Related]
19. Selective biological response by target organs (intestine, kidney, and bone) to 1,25-dihydroxyvitamin D3 and two analogues.
Norman AW; Sergeev IN; Bishop JE; Okamura WH
Cancer Res; 1993 Sep; 53(17):3935-42. PubMed ID: 8395333
[TBL] [Abstract][Full Text] [Related]
20. Novel vitamin D analogs that modulate leukemic cell growth and differentiation with little effect on either intestinal calcium absorption or bone mobilization.
Zhou JY; Norman AW; Lübbert M; Collins ED; Uskokovic MR; Koeffler HP
Blood; 1989 Jul; 74(1):82-93. PubMed ID: 2665845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
